HRAS and cancer: Given that the lysosomal Ca2+ channel TRPML1 is specifically activated in the tumor microenvironment [27] and it plays important roles in the development of many cancers, instead of targeting the lysosome, inhibiting TRPML1 channel could be a more feasible approach to treat some cancers, especially for certain cancers with significant increase in TRPML1 expression, such as those bearing HRAS mutations [89] and TNBC [78].